An observational study in Cancer and Geographic Tongue, sponsored by Instituto do Cancer do Estado de São Paulo. Completed at 1 site in Brazil. Per ClinicalTrials.gov, last updated 2025-05-25.
Sponsored by Instituto do Cancer do Estado de São Paulo · Observational
Oral clinical descriptions related to adverse events in patients treated with those elective multi-targeted receptor tyrosine kinase inhibitors and a recombinant humanised monoclonal antibody
Electronical medical and dental records, high-resolution digital photograph were reviewed. Demographic data, medical background, clinical and laboratory information were recorded for each individual case.
10,818 studies on the registry are indexed under Neoplasms; 2,324 are open to participants now.
This study's enrollment of 8 is below the median of 200 across 2,638 observational studies indexed under Neoplasms.
Browse Neoplasms studies →Instituto do Cancer do Estado de São Paulo is the lead sponsor of 91 studies on the registry; 22 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Hospital -Instituto do Cancer do Estado de Sao Paulo-ICESP
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oral clinical manifestation
Other: Clinical evaluation
treatment methods, associated symptoms, evolution and clinical presentation
Also known as: clinical images
Benign migratory glossitis
erythematous erosions, with loss of filiform papillae, surrounded by white circinate rims on the dorsal tongue
Time frame: From enrollment to the end of study at 7 years
Adverse events
Dysgeusia , dermatologic toxicities such as skin erythemas and vesicles on the palms of the hands and burning sensation
Time frame: From enrollment to the end of study at 7 years
Plan to share: Undecided — undecided
No publications or documents are linked to this record.
Ran from Jul 2017 to primary completion in Jan 2020, 29 months.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Instituto do Cancer do Estado de São Paulo